DR. ABDUL MUSTAJEEB HASEEB M.D. NPI 1407897093

NPI Details

DR. Abdul Mustajeeb Haseeb, M.D. is a hematology and oncology internal medicine in Fresno, CA with 32 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Abdul Mustajeeb Haseeb, M.D. NPI is 1407897093. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

7130 N MILLBROOK AVE
FRESNO, CA
ZIP 93720-347
Phone: (559) 326-1222
Fax: (559) 326-1230

The NPI 1407897093 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, testosterone cypionate, 1 mg (HCPCS:J1071)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Unclassified drugs (HCPCS:J3490)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Urinalysis, manual test (HCPCS:81002)
• Electrophoresis, laboratory testing technique (HCPCS:82664)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Blood test, clotting time (HCPCS:85610)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Drawing of blood for a medical problem (HCPCS:99195)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Ct scan of abdomen before and after contrast (HCPCS:74170)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Ct scan of chest with contrast (HCPCS:71260)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Vitamin d-3 level (HCPCS:82306)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Declotting of central venous tube (HCPCS:36593)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Thyroid hormone, t3 measurement, free (HCPCS:84481)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Unclassified biologics (HCPCS:J3590)
• Folic acid level, serum (HCPCS:82746)
• Thyroxine (thyroid chemical), free (HCPCS:84439)

The enumeration date for this NPI number is 6/8/2006 and was last updated on 1/27/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.